Aurobindo Pharma Secures FTC Approval for $250 Million Acquisition of Lannett Company

Aurobindo Pharma USA, a wholly-owned subsidiary of Aurobindo Pharma Limited, has received clearance from the U.S. Federal Trade Commission (FTC) to acquire Lannett Company LLC for $250 million (on a cash-free, debt-free basis). The transaction is expected to officially close by the end of June 2026. Key Deal Highlights: Target Profile: Lannett is a Pennsylvania-based pharmaceutical company specializing in complex generics and non-opioid controlled substances. Regulatory Milestone: Securing FTC approval removes the final major regulatory hurdle, paving the way for imminent closure. Strategic Rationale: Portfolio Expansion: The acquisition significantly broadens Aurobindo USA’s product range in the high-margin, complex non-opioid controlled substances segment. U.S. Manufacturing Footprint: The deal brings Lannett’s Seymour, Indiana manufacturing facility into Aurobindo’s network. The site has an impressive capacity of approximately 4 billion doses annually, directly aligning with U.S. policy goals for domestic pharmaceutical supply chain resilience. Financial & Operational Impact: Immediate EPS Accretion: The transaction is projected to be immediately accretive to Aurobindo Group’s Earnings Per Share (EPS). Synergy Realization: The integration is expected to yield substantial cost efficiencies, SG&A synergies, and operational advantages, supporting sustainable long-term growth. Outlook: This acquisition marks a major strategic leap for Aurobindo in the U.S. market, combining Lannett's specialized product pipeline and differentiated generics with robust domestic manufacturing capabilities. It positions Aurobindo to capture greater market share in complex therapies while mitigating global supply chain risks. $AUROPHARMA